EPS all four quarters 2014 beat estimates and 2015 guidance was solid and in line with estimates. Abbott looks to be pretty solid going forward. Good growth, continues good margin improvements and solid EPS growth. Did not decrease guidance like some many international companies are doing this quarter.
Good earnings report, not spectacular but still growing despite the exchange impact. I will keep my shares and look forward to steady earnings and dividend growth.
Mylan to buy Abbott business line in $5.3B deal - Abbott will own about 21% of the combined Mylan company which will be called Mylan NV but does not intend to remain a long-term shareholder. Shares of Mylan NV will trade on the Nasdaq under Mylan's existing ticker symbol, "MYL."
Galectine 3 test for HF to be supplied through with ABT Architect platform. The automated test will become standard test for Heart failure patients globally (ca 30M people, to test twice a year, at $30 per test = $1.8B revenue potential), as highly predicitive of HF and recenlty cleared by the FDA (on Dec 30th 2014). BGMD owning the IP rights of the automated Galectine 3 test has $21M market cap..., I leave it to you to guess where BGMD PPS is heading (+ 60% only last week)
Sentiment: Strong Buy
There is positive news with BGMD. You want to do a little DD on it. The way
Kingkongdingdong is putting the news out there makes it look like
he has Downs Syndrome. He makes BGMD look bad...